Therapeutic Phage Display-Derived Single-Domain Antibodies for Pandemic Preparedness

Daly, Janet M.; Lim, Theam Soon; Gough, Kevin C.

Abstract

Driven by necessity, the COVID-19 pandemic caused by SARS-CoV-2 has accelerated the development and implementation of new vaccine platforms and other viral therapeutics. Among these is the therapeutic use of antibodies including single-domain antibodies, in particular the camelid variable heavy-chain fragment (VHH). Such therapies can provide a critical interim intervention when vaccines have not yet been developed for an emerging virus. It is evident that an increasing number of different viruses are emerging and causing epidemics and pandemics with increasing frequency. It is therefore imperative that we capitalize on the experience and knowledge gained from combatting COVID-19 to be better prepared for the next pandemic.

Citation

Daly, J. M., Lim, T. S., & Gough, K. C. (2023). Therapeutic Phage Display-Derived Single-Domain Antibodies for Pandemic Preparedness. Antibodies, 12(1), Article 7. https://doi.org/10.3390/antib12010007

• Journal Article Type: Article
• Acceptance Date: Jan 9, 2023
• Online Publication Date: Jan 14, 2023
• Publication Date: Jan 14, 2023
• Deposit Date: Jan 9, 2023
• Publicly Available Date: Jan 14, 2023
• Journal: Antibodies
• Electronic ISSN: 2073-4468
• Peer Reviewed: Peer Reviewed
• Volume: 12
• Issue: 1
• Article Number: 7
• DOI: https://doi.org/10.3390/antib12010007
• Keywords: VHH, single-domain antibody, virus, therapeutic
• Public URL: https://nottingham-repository.worktribe.com/output/15926537
• Publisher URL: https://www.mdpi.com/2073-4468/12/1/7